ClinicalTrials.gg
CompletedNCT00118742Updated Aug 3, 2010Results posted

Liver Spare the Nephron (STN) Study - A Study of CellCept (Mycophenolate Mofetil) and Sirolimus in Recipients of a Liver Transplant

A Phase 4 interventional study of mycophenolate mofetil [CellCept] and Tacrolimus in Liver Transplantation, sponsored by Hoffmann-La Roche. Completed at 46 sites in 2 countries. Open to participants aged 18 Years to 74 Years. Per ClinicalTrials.gov, last updated 2010-08-03.

Sponsored by Hoffmann-La Roche · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
293
Allocation
Randomized
Ages
18 Years to 74 Years
Sex
All
01

Study summary

This two-arm study will assess the efficacy and safety of a long-term calcineurin inhibitor-free maintenance regimen with CellCept and sirolimus in recipients of an orthotropic liver transplant. Patients will be randomized to receive either CellCept 1-1.5 g twice daily (BID) + tacrolimus + cyclosporine, or CellCept 1-1.5 g BID + sirolimus. The anticipated time on study treatment is 1 to 2 years, and the target sample size is 100 to 500 individuals.

02

Conditions studied

  • Liver Transplantation
03

In context

Lead sponsor

Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.

Of its 331 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 74 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult patients 18-74 years of age
  • Single primary liver transplant from a deceased donor
  • CellCept plus tacrolimus or cyclosporine from time of transplantation (within 72 hours)
  • Patients with -positive status may be entered if they have had an intraoperative (back table) of the transplanted liver or will have a biopsy at the time of randomization. This is not required for patients negative for hepatitis C.

Exclusion criteria

Exclusion Criteria:

  • Liver allograft from a living donor or a split liver
  • Multiple organ transplant
  • Dialysis therapy for >14 days from transplantation to randomization
  • History of in the last 5 years (except hepatoma or non-melanoma skin cancer)
  • Previous sirolimus therapy
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
293 participants (actual)

Study arms

  • Experimental
    CellCept + CNI (tacrolimus or cyclosporine)

    Drug: mycophenolate mofetil [CellCept] · Drug: Tacrolimus · Drug: Cyclosporine

  • Active comparator
    CellCept + sirolimus

    Drug: mycophenolate mofetil [CellCept] · Drug: Sirolimus

Interventions

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Glomerular Filtration Rate (GFR) at 12 Months Posttransplant

    Mean percent change from baseline in estimated glomerular filtration rate (GFR) calculated by modification of diet in renal disease (MDRD)-6 variable equation at 12 months posttransplantation. MDRD-6 variables: serum creatinine, albumin and urea nitrogen, gender, age and ethnicity.

    Time frame: 12 months posttransplant

Secondary outcomes

  1. Change From Baseline in Glomerular Filtration Rate (GFR) at 6 Months Posttransplant

    Mean percent change from baseline in estimated GFR calculated by modification of diet in renal disease (MDRD)-6 variable equation at 6 and 24 months posttransplantation. MDRD-6 variables: serum creatinine, albumin and urea nitrogen, gender, age and ethnicity.

    Time frame: 6 months posttransplant

  2. Change From Baseline in Glomerular Filtration Rate (GFR) at 24 Months Posttransplant

    Mean percent change from baseline in estimated GFR calculated by modification of diet in renal disease (MDRD)-6 variable equation at 6 and 24 months posttransplantation. MDRD-6 variables: serum creatinine, albumin and urea nitrogen, gender, age and ethnicity.

    Time frame: 24 months posttransplant

  3. Change From Baseline in Creatinine Clearance

    Mean percent change from baseline in calculated creatinine clearance (CL) at 6, 12, and 24 months posttransplantation

    Time frame: 6, 12, and 24 months posttransplantation

07

Results

Posted Mar 10, 2010
Limitations and caveats
There were no overall limitations and caveats.

Participant flow

Patients were recruited from 43 study centers in the US and Canada over a period of 3 years (24-Aug-05 to 03-Jul-08)

Participant flow — Overall Study
MilestoneCellCept + CNI (Tacrolimus or Cyclosporine)CellCept + Sirolimus
Started145148
Completed9682
Not completed4966

Outcome measures

PrimaryChange From Baseline in Glomerular Filtration Rate (GFR) at 12 Months Posttransplant

Mean percent change from baseline in estimated glomerular filtration rate (GFR) calculated by modification of diet in renal disease (MDRD)-6 variable equation at 12 months posttransplantation. MDRD-6 variables: serum creatinine, albumin and urea nitrogen, gender, age and ethnicity.

Time frame:
12 months posttransplant
Reported as:
Mean · Percent change in GFR (mL/min)
Change From Baseline in Glomerular Filtration Rate (GFR) at 12 Months Posttransplant
Percent change in GFR (mL/min)CellCept + CNI (Tacrolimus or Cyclosporine)CellCept + Sirolimus
Change From Baseline in Glomerular Filtration Rate (GFR) at 12 Months Posttransplant1.2 ± 39.8619.7 ± 40.64
Statistical analysis
  • CellCept + CNI (Tacrolimus or Cyclosporine) vs CellCept + Sirolimus · ANCOVA · p = 0.0012 · Mean difference (final values): 24.9 · 95% CI 14.8 to 35.0
SecondaryChange From Baseline in Glomerular Filtration Rate (GFR) at 6 Months Posttransplant

Mean percent change from baseline in estimated GFR calculated by modification of diet in renal disease (MDRD)-6 variable equation at 6 and 24 months posttransplantation. MDRD-6 variables: serum creatinine, albumin and urea nitrogen, gender, age and ethnicity.

Time frame:
6 months posttransplant
Reported as:
Mean · Percent change in GFR (mL/min)
Change From Baseline in Glomerular Filtration Rate (GFR) at 6 Months Posttransplant
Percent change in GFR (mL/min)CellCept + CNI (Tacrolimus or Cyclosporine)CellCept + Sirolimus
Change From Baseline in Glomerular Filtration Rate (GFR) at 6 Months Posttransplant1.1 ± 24.3925.5 ± 45.82
Statistical analysis
  • CellCept + CNI (Tacrolimus or Cyclosporine) vs CellCept + Sirolimus · ANCOVA · p = <0.0001 · Mean difference (final values): 25.6 · 95% CI 15.7 to 35.6
SecondaryChange From Baseline in Glomerular Filtration Rate (GFR) at 24 Months Posttransplant

Mean percent change from baseline in estimated GFR calculated by modification of diet in renal disease (MDRD)-6 variable equation at 6 and 24 months posttransplantation. MDRD-6 variables: serum creatinine, albumin and urea nitrogen, gender, age and ethnicity.

Time frame:
24 months posttransplant
Reported as:
Mean · Mean percent change in GFR (mL/min)
Change From Baseline in Glomerular Filtration Rate (GFR) at 24 Months Posttransplant
Mean percent change in GFR (mL/min)CellCept + CNI (Tacrolimus or Cyclosporine)CellCept + Sirolimus
Change From Baseline in Glomerular Filtration Rate (GFR) at 24 Months Posttransplant-8.6 ± 43.3713.5 ± 49.17
Statistical analysis
  • CellCept + CNI (Tacrolimus or Cyclosporine) vs CellCept + Sirolimus · ANCOVA · p = 0.0053 · Mean difference (final values): 28.7 · 95% CI 13.7 to 43.7
SecondaryChange From Baseline in Creatinine Clearance

Mean percent change from baseline in calculated creatinine clearance (CL) at 6, 12, and 24 months posttransplantation

Time frame:
6, 12, and 24 months posttransplantation
Reported as:
Mean · Percent change in creatinine CL (mL/min)
Change From Baseline in Creatinine Clearance
Percent change in creatinine CL (mL/min)CellCept + CNI (Tacrolimus or Cyclosporine)CellCept + Sirolimus
6 months-1.3 ± 23.7118.5 ± 39.93
12 months-3.0 ± 35.8614.0 ± 35.16
24 months-12.8 ± 41.647.9 ± 44.36
Statistical analysis
  • CellCept + CNI (Tacrolimus or Cyclosporine) vs CellCept + Sirolimus · ANCOVA · p = <0.0001 · Median difference (final values): 21.1 · 95% CI 12.5 to 29.6
  • CellCept + CNI (Tacrolimus or Cyclosporine) vs CellCept + Sirolimus · ANCOVA · p = <0.0001 · Mean difference (final values): 18.2 · 95% CI 9.9 to 26.6
  • CellCept + CNI (Tacrolimus or Cyclosporine) vs CellCept + Sirolimus · ANCOVA · p = 0.0006 · Mean difference (final values): 23.6 · 95% CI 10.2 to 37.0

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
CellCept + CNI (Tacrolimus or Cyclosporine)—65/146 (44.5%)134/146 (91.8%)
CellCept + Sirolimus—67/148 (45.3%)141/148 (95.3%)
Most frequent serious events
Showing 10 of 152
Most frequent serious events
EventCellCept + CNI (Tacrolimus or Cyclosporine)CellCept + Sirolimus
Hepatitis CInfections and infestations10/1468/148
PyrexiaGeneral disorders1/1467/148
Renal FailureRenal and urinary disorders5/1460/148
Incisional HerniaInjury, poisoning and procedural complications4/1464/148
Pleural EffusionRespiratory, thoracic and mediastinal disorders4/1460/148
HyperkalaemiaMetabolism and nutrition disorders4/1460/148
CholangitisHepatobiliary disorders0/1464/148
AnaemiaBlood and lymphatic system disorders1/1464/148
Deep Vein ThrombosisVascular disorders2/1464/148
PneumoniaInfections and infestations3/1462/148
Most frequent other events
Showing 10 of 55
Most frequent other events
EventCellCept + CNI (Tacrolimus or Cyclosporine)CellCept + Sirolimus
DiarrhoeaGastrointestinal disorders42/14637/148
HeadacheNervous system disorders24/14638/148
LeukopeniaBlood and lymphatic system disorders21/14635/148
Oedema PeripheralGeneral disorders17/14627/148
Abdominal PainGastrointestinal disorders26/14621/148
FatigueGeneral disorders23/14626/148
RashSkin and subcutaneous tissue disorders5/14626/148
PyrexiaGeneral disorders21/14625/148
NauseaGastrointestinal disorders23/14619/148
Hepatitis CInfections and infestations23/14620/148

Baseline characteristics

Age Continuous
Age Continuous(years)CellCept + CNI (Tacrolimus or Cyclosporine)CellCept + SirolimusTotal
Mean53.4 ± 7.8853.2 ± 8.8353.3 ± 8.36
Sex: Female, Male
Sex: Female, Male(Participants)CellCept + CNI (Tacrolimus or Cyclosporine)CellCept + SirolimusTotal
Female353873
Male110110220
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)CellCept + CNI (Tacrolimus or Cyclosporine)CellCept + SirolimusTotal
American Indian347
Asian or Pacific Islander31114
Black11819
White126125251
Other202
Height
Height(cm)CellCept + CNI (Tacrolimus or Cyclosporine)CellCept + SirolimusTotal
Mean173.6 ± 10.04173.0 ± 10.26173.3 ± 10.14
Weight
Weight(kg)CellCept + CNI (Tacrolimus or Cyclosporine)CellCept + SirolimusTotal
Mean79 ± 16.3277.9 ± 17.5678.4 ± 16.94
08

Study locations

46 sites
  • Birmingham, Alabama 35294, United States
  • Phoenix, Arizona 85054, United States
  • La Jolla, California 92037, United States
  • Los Angeles, California 90033-4612, United States
  • Los Angeles, California 90095, United States
  • San Diego, California 92103-8401, United States
  • San Francisco, California 94115, United States
  • San Francisco, California 94143-0780, United States
  • Denver, Colorado 80262, United States
  • Jacksonville, Florida 32216, United States
  • Miami, Florida 33136, United States
  • Tampa, Florida 33606, United States
  • Atlanta, Georgia 30322, United States
  • Chicago, Illinois 60611, United States
  • Chicago, Illinois 60612-3824, United States
  • New Orleans, Louisiana 70121, United States
  • Baltimore, Maryland 21201, United States
  • Boston, Massachusetts 02111, United States
  • Boston, Massachusetts 02114-2696, United States
  • Boston, Massachusetts 02215, United States
  • Burlington, Massachusetts 01805, United States
  • Detroit, Michigan 48202-2689, United States
  • Minneapolis, Minnesota 55455, United States
  • Rochester, Minnesota 55905, United States
  • St Louis, Missouri 63110, United States
  • Newark, New Jersey 07101-1709, United States
  • Hawthorne, New York 10532, United States
  • New York, New York 10016, United States
  • New York, New York 10029, United States
  • New York, New York 10032, United States
  • Chapel Hill, North Carolina 27599, United States
  • Cleveland, Ohio 44195, United States
  • Oklahoma City, Oklahoma 73112-4481, United States
  • Portland, Oregon 97201-3098, United States
  • Philadelphia, Pennsylvania 19141, United States
  • Nashville, Tennessee 37232, United States
  • Dallas, Texas 75246, United States
  • Houston, Texas 77030, United States
  • San Antonio, Texas 78284, United States
  • Richmond, Virginia 23298, United States
  • Madison, Wisconsin 53792, United States
  • Edmonton, Alberta T6G 2B7, Canada
  • Halifax, Nova Scotia B3H 3A7, Canada
  • London, Ontario N6A 5A5, Canada
  • Montreal, Quebec H2X 3J4, Canada
  • Montreal, Quebec H3A 1A1, Canada
09

References and documents

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2005, a primary completion of Jul 2008 and a completion of Dec 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Mar 2010, 1 year 8 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 30, 2005
First posted
Jul 12, 2005
Start
Aug 2005
Primary completionActual
Jul 2008
CompletionActual
Dec 2008
Results first posted
Mar 10, 2010
Last update
Aug 3, 2010
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 3, 2010, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00118742
Lead sponsor
Hoffmann-La Roche
First posted
Jul 12, 2005
Start date
Aug 2005
Primary completion
Jul 2008
Completion
Dec 2008
Results posted
Mar 10, 2010
Last update
Aug 3, 2010

Study contacts

Clinical Trials
study director · Hoffmann-La Roche
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2010. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Tacrolimus · Cyclosporine

Start the discussion